Cardiff Oncology Inc Stock
Cardiff Oncology Inc Stock price
Key metrics
| Market capitalization | $287.36m |
| Enterprise Value | $231.38m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| EV/Sales (TTM) EV/Sales | 335.33 |
| P/S ratio (TTM) P/S ratio | 416.46 |
| P/B ratio (TTM) P/B ratio | 4.26 |
| Revenue growth (TTM) Revenue growth | 49.78% |
| Revenue (TTM) Revenue | $690.00k |
Is Cardiff Oncology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
Cardiff Oncology Inc Stock Analysis
Analyst Opinions
5 Analysts have issued a Cardiff Oncology Inc forecast:
Analyst Opinions
5 Analysts have issued a Cardiff Oncology Inc forecast:
Financial data from Cardiff Oncology Inc
| Sep '24 |
+/-
%
|
||
| Revenue | 0.69 0.69 |
50%
50%
|
|
| Gross Profit | 0.28 0.28 |
133%
133%
|
|
| EBITDA | -46 -46 |
4%
4%
|
EBIT (Operating Income) EBIT | -46 -46 |
4%
4%
|
| Net Profit | -43 -43 |
5%
5%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Cardiff Oncology Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cardiff Oncology Inc Stock News
Company Profile
Cardiff Oncology, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. It primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
| Head office | United States |
| CEO | Mark Erlander |
| Employees | 32 |
| Founded | 1999 |
| Website | www.cardiffoncology.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
